Celgene (CELG +6.9%) shares rise on speculation that a positive resolution of a European...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG +6.9%) shares rise on speculation that a positive resolution of a European regulatory review of its Revlimid cancer drug could be imminent. Analysts say the EU advisory panel meeting this week may support the drug's overall risk/benefit ratio after clinical data suggested increased risk of secondary malignancies in long-term users.